Sartorius has bolstered its virus clearance R&D capabilities in Lanarkshire, Scotland after signing a 15-year lease. The deal, of which financial details have not been disclosed, sees German life sciences firm Sartorius take over more than 8,500 square-feet within Maxim 3 at the Eurocentral park for various research. Lonza already has a presence in Glasgow, Scotland with a competence center for bioanalytics and a small team of experts for virus clearance services following its acquisition of BioOutsource in 2015. “This…

Lonza will invest in additional drug product manufacturing capabilities in Switzerland to accelerate existing service offerings in Basel and Visp. The expansion will see contract development manufacturing organization (CDMO) Lonza install an aseptic fill-finish line in Stein, Switzerland and expand drug product services in Basel and Visp. “We constantly assess our assets and invest in developing and installing new capacity and technology to meet the market demand in biologics,” Peter Droc, head of drug product services at Lonza told BioProcess…